Precede Biosciences’ Post

How are advanced #AI tools for prostate cancer #riskstratification, such as the ArteraAI Prostate Test, transforming how we counsel our patients regarding treatment and outcomes? Rashid Sayyid, Urologic Oncology Fellow at the University of Toronto, and Zach Klaassen, Associate Professor and Program Director at Wellstar MCG Health, discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification in #prostatecancer management, in a new video with Urology Today:

My latest for Health -- A new urine test, called MyProstateScore 2.0 (MPS2), may be able to identify more aggressive, high-grade prostate cancers. Experts say the test could help eliminate unnecessary biopsies in men who have low-grade cancer. MPS2 is available now, however, more research is needed to determine how the test functions in racially diverse populations. Big thank you to study author Arul Chinnaiyan, MD, PhD, director of the Michigan Center for Translational Pathology at the University of Michigan Medical School, Mark Katz, MD, clinical associate professor of urology at the Boston University School of Medicine, and Sam Haywood, MD, urologic oncologist at Cleveland Clinic, for sharing their expertise with me! #prostatecancer #prostatecancertest #prostatecancerresearch #cancer #cancerresearch #health #healthnews

A meta-analysis by Dr Sharron Liang and A/Prof Andrew Field from the Anatomical Pathology team at SydPath | St Vincent’s Pathology Sydney is available via early view in the American Cancer Society Journal - Cancer Cytopathology. The Sydney system for lymph node FNA biopsy cytopathology: A detailed analysis of recent publications and meta-analysis and a proposal for the components of an ideal prospective study of a cytopathology reporting system. #fna #fineneedleaspiration #metaanalysis #cytopathology #cytology #pathology #reporting #anatomicalpathology #diagnostics #research

RESEARCH UPDATE Susannah Patey (2008 Fellow) Systemic anti-cancer therapy and anaesthesia: a narrative review https://lnkd.in/edSeKBdz Michael Johnson (1985 Fellow) Cell state-dependent allelic effects and contextual Mendelian randomization analysis for human brain phenotypes https://lnkd.in/ezFnEcZS #science #medicine #research #cancer #anaesthesia #genetics

Urology Practice publishes peer-reviewed study authored by Dr. Keith Crawford and Thomas Farrington of The Prostate Health Education Network (PHEN) and PCCTC CEO Jake Vinson identifying factors affecting the accrual of Black males into prostate cancer clinical trials in the United States. Full article can be found here: https://lnkd.in/eqEbHF9v

In this interview, Michael Leapman, MD, MHS, and Preston Sprenkle, MD, discuss the study, “Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage,” for which they served as the lead and senior authors, respectively. Leapman is a urologic oncologist, a prostate cancer clinician, and an associate professor of urology at Yale University School of Medicine, and Sprenkle is a urologic oncologist and an associate professor of urology at Yale University School of Medicine in New Haven, Connecticut. Click here to learn more: https://lnkd.in/dnjBennN #Cancer #ProstateCancer #GenomicTesting #MedicalResearch #ClinicalData #Oncology #CancerResearch #Urology #PrecisionMedicine #GenomicData #Biobank #Databank Urology Times

Proud of our #nucmed chief resident Divya Yadav, who did a beautiful job with this research project, taking it from data collection / analysis to Radiological Society of North America (RSNA) abstract to publication 👏 over the course of the past year. In this study, we show that dural based #metastases, a rare but important diagnosis in patients with #prostatecancer, can be differentiated from #meningioma, the most common brain tumor, using #PSMA #PET. This highlights targeted PET as an important adjunct modality in the management of patients with #prostatecancer https://lnkd.in/e9nyXf7n Many thanks to our multi-disciplinary team Silvina Dutruel, MD Andres Ricaurte-Fajardo Susan Pannullo Jonathan Knisely Rituraj Upadhyay Joshua Palmer Scott Tagawa Joseph Osborne Andrew Brandmaier Weill Cornell Medicine Cornell Molecular Imaging and Therapeutics

1 in 8 men will develop #prostatecancer, and while most cases are not fatal, prostate #cancer kills approximately 34,000 Americans every year. Learn more about the prostate cancer data we have available for research: https://tr.vet/4aAWq6N #rwe #rwd #cancerdata #clinicalinsights #diseaseburden

Prostate-specific membrane antigen #petscan can improve the length and quality of life for patients with recurrent prostate cancer, UK researchers have reported. https://buff.ly/3UnxlHa #Radiology #NucMed

I'm excited to share a recent publication in *European Urology* that highlights the potential of Prostate-Specific Membrane Antigen (PSMA) as a biomarker in treatment-naïve prostate cancer. The study, led by Dr. Adam B. Weiner from Cedars-Sinai Medical Center, reveals that PSMA expression levels are associated with cancer biology and treatment sensitivities. This finding suggests that PSMA could be instrumental in tailoring treatments for patients with newly diagnosed prostate cancer. In the U.S., PSMA PET scans are commonly used for staging prostate cancer, but not all tumors express PSMA. These variations in expression may reflect underlying differences in cancer biology, a concept previously observed in advanced metastatic prostate cancer. This research underscores the importance of understanding PSMA expression in early-stage prostate cancer to optimize treatment strategies. This advancement could pave the way for more personalized and effective treatment plans, potentially improving outcomes for many patients. https://lnkd.in/eMmgVGtf #ProstateCancer #PSMA #CancerResearch #PersonalizedMedicine #Urology #HealthcareInnovation #MedicalResearch #Oncology #Biomarkers #PatientCare